Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma

Neoplasia (United States)

Volumn 14, Issue 12, 2012, Pages 1178-1189

  Wu, Xiaosong ^a   Tao, Yi ^a   Hou, Jun ^a   Meng, Xiuqin ^a   Shi, Jumei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BINDING PROTEIN; LIPOCORTIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN KINASE B; UL 16 BINDING PROTEIN 2; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CHROMIUM 51 RELEASE; CONTROLLED STUDY; DEGRANULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MYELOMA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84871566579     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121236     Document Type: Article

References (49)

1. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, and Anderson K (2012). Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9, 135-143.
2. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, and Mohty M (2012). Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia 26, 73-85.
3. Topalian SL, Weiner GJ, and Pardoll DM (2011). Cancer immunotherapy comes of age. J Clin Oncol 29, 4828-4836.
4. Ruggeri L, Zhang S, and Farag SS (2009). Natural killer cell activity and killer immunoglobulin-like receptors in hematopoietic stem cell transplantation. Cancer Treat Res 144, 47-69.
5. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, and Spies T (1999). Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729.
6. Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, and Chalupny NJ (2001). ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133.
7. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, and Durrant LG (2006). Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 118, 1445-1452.
8. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al. (2005). Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65, 6321-6329.
9. - antitumor T cells. Cancer Res 64, 2175-2182.
10. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M, et al. (2007). Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 21, 2103-2108.
11. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, and Odum N (2005). Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65, 11136-11145.
12. Tieng V, Le Bouguénec C, du Merle L, Bertheau P, Desreumaux P, Janin A, Charron D, and Toubert A (2002). Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA 99, 2977-2982.
13. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, and Spies T (2001). Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2, 255-260.
14. Blaheta RA and Cinatl J Jr (2002). Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22, 492-511.
15. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, et al. (2008). NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111, 1428-1436.
16. Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, and Nakao S (2010). Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 101, 609-615.
17. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, and Kornhuber B (1996). Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7, 766-773.
18. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, and Strominger JL (1999). Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA 96, 5640-5644.
19. Bryceson YT, March ME, Barber DF, Ljunggren HG, and Long EO (2005). Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 202, 1001-1012.
20. Borchers MT, Harris NL, Wesselkamper SC, Vitucci M, and Cosman D (2006). NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 291, L222-L231.
21. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX, et al. (2006). BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 176, 5108-5116.
22. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, and Hayakawa Y (2005). NKG2D function protects the host from tumor initiation. J Exp Med 202, 583-588.
23. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, and Raulet DH (2008). NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571-580.
24. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, and Weller M (2004). RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64, 7596-7603.
25. Zitvogel L, Apetoh L, Ghiringhelli F, and Kroemer G (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8, 59-73.
26. Ullrich E, Bonmort M, Mignot G, Kroemer G, and Zitvogel L (2008). Tumor stress, cell death and the ensuing immune response. Cell Death Differ 15, 21-28.
27. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, and Kroemer G (2008). The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118, 1991-2001.
28. González S, Groh V, and Spies T (2006). Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298, 121-138.
29. Okamoto M, Inaba T, Yamada N, Uchida R, Fuchida SI, Okano A, Shimazaki C, and Taniwaki M (2006). Expression and role of MHC class I-related chain in myeloma cells. Cytotherapy 8, 509-516.
30. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, and Zocchi MR (2009). Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23, 641-648.
31. Chávez-Blanco A, Cruz-Hernández de la E, Domínguez GI, Rodríguez-Cortez O, Alatorre B, Pérez-Cárdenas E, Chacón-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, et al. (2011). Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol 39, 1491-1499.
32. Raulet DH (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3, 781-790.
33. Gleimer M and Parham P (2003). Stress management: MHC class I and class I-like molecules as reporters of cellular stress. Immunity 19, 469-477.
34. Unni AM, Bondar T, and Medzhitov R (2008). Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci USA 105, 1686-1691.
35. Gasser S, Orsulic S, Brown EJ, and Raulet DH (2005). The DNA damage path-way regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190.
36. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, and Santoni A (2007). Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110, 606-615.
37. Molinero LL, Fuertes MB, Girart MV, Fainboim L, Rabinovich GA, Costas MA, and Zwirner NW (2004). NF-κB regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol 173, 5583-5590.
38. López-Soto A, Quiñones-Lombraña A, López-Arbesú R, López-Larrea C, and González S (2006). Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem 281, 30419-30430.
39. Venkataraman GM, Suciu D, Groh V, Boss JM, and Spies T (2007). Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 178, 961-969.
40. Zhang C, Wang Y, Zhou Z, Zhang J, and Tian Z (2009). Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58, 1275-1285.
41. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, and Lutz CT (2009). Proteasome regulation of ULBP1 transcription. J Immunol 182, 6600-6609.
42. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, Grafone T, Martinelli G, Conte R, and Martelli AM (2005). Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 129, 677-686.
43. Grandage VL, Gale RE, Linch DC, and Khwaja A (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, Mapkinase and p53 pathways. Leukemia 19, 586-594.
44. Yin B, Morgan K, Hasz DE, Mao Z, and Largaespada DA (2006). Nf l gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia 20, 151-154.
45. Ogbomo H, Michaelis M, Klassert D, Doerr HW, and Cinatl J Jr (2008). Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia 10, 1402-1410.
46. Xu Q, Garraway SM, Weyerbacher AR, Shin SJ, and Inturrisi CE (2008). Activation of the neuronal extracellular signal-regulated kinase 2 in the spinal cord dorsal horn is required for complete Freund's adjuvant-induced pain hypersensitivity. J Neurosci 28, 14087-14096.
47. Frémin C, Ezan F, Boisselier P, Bessard A, Pagès G, Pouysségur J, and Baffet G (2007). ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes. Hepatology 45, 1035-1045.
48. Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W, Welzl H, Wolfer DP, Pagès G, Valverde O, et al. (2002). Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 34, 807-820.
49. López-Larrea C, Suárez-Alvarez B, López-Soto A, López-Vázquez A, and Gonzalez S (2008). The NKG2D receptor: sensing stressed cells. Trends Mol Med 14, 179-189.